Xu-Shan Sun

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 163 citations · Full text

Solid Cancer Patients, Cancer Epidemiology, Disease Risk Assessment +12

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau et al. · The Lancet Oncology · 2020 · 124 citations

Radiation Therapy, Medicine, High-dose Cisplatin Chemoradiotherapy +9

Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)

Yungan Tao, Anne Aupérin, Xu-Shan Sun et al. · European Journal of Cancer · 2020 · 91 citations · Full text

Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy

Maciej Krzakowski, Rodryg Ramlau, Jacek Jassem et al. · Journal of Clinical Oncology · 2010 · 75 citations

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Yungan Tao, Xu-Shan Sun, Y. Pointreau et al. · European Journal of Cancer · 2023 · 48 citations · Full text